Searched for
AUROBINDO PHARMA PRODUCTION
US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisitionThe U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Buy capital goods on dips, stay cautious on IT and consumption: Sudip BandyopadhyayMarket expert Sudip Bandyopadhyay outlines investment strategies across key sectors. He sees opportunities in State Bank of India and a gen...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...
- AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 croreThe land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Fire at subsidiary unit temporarily hits production: Aurobindo PharmaAurobindo Pharma reported a fire incident on September 18, 2025, at its APL Healthcare Unit-IV in Andhra Pradesh due to a short circuit, ca...
- Aurobindo joins hands with global pharma player to develop respiratory productsAurobindo Pharma's US subsidiary has partnered with a global pharmaceutical company to develop and sell respiratory products. The collabora...
- Aurobindo to acquire 49 pc stake in GLS Pharma for Rs 22.5 crAurobindo Pharma Ltd will acquire the remaining 49% stake in GLS Pharma Ltd for Rs 22.5 crore, making it a wholly-owned subsidiary. The acq...
- Aurobindo Pharma gets USFDA nod for anaesthesia drugQuoting IQVIA data, Aurobindo Pharma said the approved product has an estimated market size of USD 11 million for the 12 months ending Sept...
- Aurobindo Pharma gets USFDA nod to market kidney ailment drugAurobindo Pharma has a total of 331 ANDA approvals (294 final nod, including 16 from Aurolife Pharma LLC and 37 tentative approvals) from t...
- Aurobindo divests Australian arm to Eris PharmaAPL will continue to manufacture and supply products to Eris Pharma for Australian and New Zealand markets over the next few years.
- Buy Aurobindo Pharma Ltd with a target of Rs 960: Prakash Gaba"Aurobindo Pharma Ltd is a 'BUY' call with a target of Rs 960 and stop loss of 917."
Load More
